Joris van de Haar

Clinician-scientist / Precision medicine / cancer immunology / bioinformatics / MD, PhD

[Joris van de Haar @Joris_vd_Haar]

@NKI_nl @oncode

[Joris van de Haar @Joris_vd_Haar]

Postdoc alert in spatial biology!

Building upon our previous work with MSI cancers (e.g. de Vries, Nature, 2023), the Voest Group at the NKI is hiring a (fully funded) postdoctoral fellow with strong expertise in spatial cancer biology.

Learn more: https://t.co/pZG6bXcA7H

[Arndt Vogel @ArndtVogel]

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
@Annals_Oncology
https://t.co/AXAHxBeSPZ
👉Clear guidance to define and improvequality standards for MTBs
@myESMO @EASLedu

[ESMO - Eur. Oncology @myESMO]

Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice.
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: https://t.co/vd2FW8ZVBC

@BenWestphalen @Annals_Oncology

[The Netherlands Cancer Institute @NKI_nl]

🎓 PhD candidate Laurien Zeverijn looked at how patients with microsatellite instability could be treated with a drug that matches their unique tumor profile. This treatment is now covered by insurance ➡️ @hetAVL @uniutrecht @flevoziekenhuis https://t.co/5QiGWphAGz
#PhDlife#PhD

[Joris van de Haar @Joris_vd_Haar]

Very well-deserved recognition for @deVisserKarin !
A fantastic scientist and example for many @NKI_nl

[EACR @EACRnews]

Please join us in congratulating our 2025 winner of the prestigious @pezcoller-EACR Women in Cancer Research Award, @deVisserKarin 👏

Our deserving winner will deliver her Award Lecture at the #EACR2025 Congress in Lisbon next year!

https://t.co/kCmzehdA6Y

[The Netherlands Cancer Institute @NKI_nl]

📢 Applications for the NKI PhD program open from Jan 1 - Feb 28. Join our international research community in Amsterdam, working in cancer biology, AI research & life sciences with leading scientists and top facilities #PhD #CancerResearch More info: https://t.co/Ln7xs1zphE

[Joris van de Haar @Joris_vd_Haar]

Congrats to @Schumacher_lab for this very well deserved recognition. One of the smartest people I know and a great role model to look up to for me and many others

[ESMO - Eur. Oncology @myESMO]

.@Schumacher_lab was bestowed the 2024 ESMO Award for Immuno-Oncology. He will deliver his award lecture on Wednesday, 11 December 2024 at the opening session of #ESMOImmuno24.
📌https://t.co/Zj6zXD33Gt

[Joris van de Haar @Joris_vd_Haar]

@djkloosterman Haha brilliant 👌

[Joris van de Haar @Joris_vd_Haar]

@lab_kok @NKI_nl @NatureMedicine Very nice work @lab_kok, congrats!

[Joris van de Haar @Joris_vd_Haar]

@MyriamChalabi @DrChoueiri @FAndreMD @myESMO @RebeccaDSing Very exciting Myriam, congrats!

[Elisabeth Bik @MicrobiomDigest]

AI can be used to make convincing looking fake data.
There is no way we can distinguish real from fake anymore.
It is safe to assume that genAI has already resulted in many fake papers. Scientific publishing is not prepared for this.

[Vivek Subbiah, MD @VivekSubbiah]

🚨🥁 Hot off the press 👉 Presenting to the world a future framework for Tissue agnostic drug development - Special article published @Annals_Oncology
–an @X 'torial for this major milestone in #precisionMedicine
✅1/n - “The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development” @myESMO
Link: https://t.co/DURYMxWC2b
👉The European Society for Medical Oncology (ESMO) Precision Medicine Working Group (PMWG) coordinated a project to optimise tumour-agnostic drug development. Represents an amazing body of insightful work by amazing colleagues - @BenWestphalen et al
🥁Huge shout out to @DMBranco & special thanks to @GPentheroudakis - CMO ESMO to help us get to the finish line , @FAndreMD for the support & @sjezdic - for her exceptional efforts in keeping us on track.
👉Delighted to share this as part of a SPECIAL @myESMO & @ASCO joint session in Barcelona, Spain - "Tumour-agnostic drug development" at the ESMO congress 2024 - session chaired by both ASCO & ESMO Presidents #ESMO24 @OncoAlert @SarahCannonDocs
🗓️ 10:15 - 11:45
📍 Oviedo Auditorium - Hall 3
👉When : Sun, 15.09.2024
Link: https://t.co/CbIeLrZWEH

[Joris van de Haar @Joris_vd_Haar]

@LeilaAkkari1 @djkloosterman @CellCellPress Very cool and original story, congrats @LeilaAkkari1, @djkloosterman & team!

[Joris van de Haar @Joris_vd_Haar]

Huge congrats to @HaanenJohn, a true inspiration! Very well deserved for his transformative work and leadership @NKI_nl

[ESMO - Eur. Oncology @myESMO]

#ESMO24: ESMO has announced the recipients of the 2024 ESMO Society Awards in recognition of their work in strengthening the oncology field and supporting fellow oncologists in their professional careers.
📌https://t.co/llnv5PS2as

[Joris van de Haar @Joris_vd_Haar]

@oncodaily

[Joris van de Haar @Joris_vd_Haar]

Our latest: The innate immune landscape of dMMR/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol

4 key novelties below 👇

[Joris van de Haar @Joris_vd_Haar]

@NKI_nl @OncoAlert @oncodeinstitute @HartwigMedical

#Oncology #precision medicine